u/marit_mensa

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

Right. And a blank between injections settles the carryover argument before it starts.

Mass spectrometry answers identity.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

identity before purity, every time, for anything unusual

England, Scotland, Wales and Northern Ireland are four different pathways

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

ghost peak, check the plumbing first, it is always the plumbing

Reading a trace posted here, in the order I actually look at things.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

the sequence is the product, everything else is packaging

a shoulder is not an impurity until you can resolve it

reproducibility beats resolution if you only get one of them

the column has a history and it shows in the peak shape

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

Stocked lines and made-to-order lines have different lead times and different storage histories. Both are ordinary; the difference is worth confirming before you commit.

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

the same name covers several different molecules in this space

Switched pharmacies mid-titration and had to restart the ladder because the concentrations did not line up.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

specialist service, not GP, for tier 3 in most of England

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

a mass spectrum costs little and answers the real question

How long have you been on the list, and from what date?

How long have you been on the list, and from what date?

you cannot report to two decimals off that baseline

Left up.

Adding the practical bit — ask what happens at discharge before you start, not after.

handling and storage vary enormously across this catalogue

That figure cannot be quoted to two decimals off that baseline. The precision is not in the data.

This. A shoulder that does not baseline-resolve is a question, not a quantity.

Has anyone here tested that compound at all?

Stocked line or made to order — did they say?

identity before purity, every time, for anything unusual

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

England, Scotland, Wales and Northern Ireland are four different pathways

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

the Irish scheme cap is the single most useful fact in this board

lyophilised and stored cold is the default for a reason

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.